Browse

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

AI Prognosis: The release of Claude Science suggests big model makers are getting serious about real science, and not just flashy problems.

Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists. It’s a piece…